Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Frog molecule could provide drug treatment for brain tumours

27.06.2007
A synthetic version of a molecule found in the egg cells of the Northern Leopard frog (Rana pipiens) could provide the world with the first drug treatment for brain tumours.

Known as Amphinase, the molecule recognises the sugary coating found on a tumour cell and binds to its surface before invading the cell and inactivating the RNA it contains, causing the tumour to die.

In new research published in the Journal of Molecular Biology, scientists from the University of Bath (UK) and Alfacell Corporation (USA) describe the first complete analysis of the structural and chemical properties of the molecule.

Although it could potentially be used as a treatment for many forms of cancer, Amphinase offers greatest hope in the treatment of brain tumours, for which complex surgery and chemotherapy are the only current treatments.

... more about:
»Amphinase »ribonuclease »trials »tumour

“This is a very exciting molecule,” said Professor Ravi Acharya, from the Department of Biology & Biochemistry at the University of Bath.

“It is rather like Mother Nature’s very own magic bullet for recognising and destroying cancer cells.

“It is highly specific at hunting and destroying tumour cells, is easily synthesised in the laboratory and offers great hope as a therapeutic treatment of the future.”

Amphinase is a version of a ribonuclease enzyme that has been isolated from the oocytes (egg cells) of the Northern Leopard frog.

Ribonucleases are a common type of enzyme found in all organisms. They are responsible for tidying up free-floating strands of RNA cells by latching on to the molecule and cutting it into smaller sections.

In areas of the cell where the RNA is needed for essential functions, ribonucleases are prevented from working by inhibitor molecules. But because Amphinase is an amphibian ribonuclease, it can evade the mammalian inhibitor molecules to attack the cancer cells.

As a treatment, it is most likely to be injected into the area where it is needed. It will have no effect on other cells because it is only capable of recognising and binding to the sugar coating of tumour cells.

“Amphinase is in the very early stages of development, so it is likely to be several years and many trials before it could be developed into a treatment for patients,” said Professor Acharya and his colleagues Drs Umesh Singh and Daniel Holloway.

“Having said that, the early data is promising and through this study we have provided the kind of information needed if approval for use is requested in the future.”

Amphinase is the second anti-tumour ribonuclease to be isolated by Alfacell Corporation from Rana pipiens oocytes.

The other, ONCONASE(R) (ranpirnase), is currently in late-stage clinical trials as a treatment for unresectable malignant mesothelioma, a rare and fatal form of lung cancer, and in Phase I/II clinical trials in non-small cell lung cancer and other solid tumours.

“We are pleased with the superb work performed by Professor Acharya and his talented team at the University of Bath,” commented Kuslima Shogen, Alfacell’s chairman and chief executive officer.

“Their work is critical to the continued development and understanding of our family of novel ribonuclease based therapeutics with the potential to help patients suffering from cancer and other dismal diseases.”

The company is now working on pre-clinical trials of Amphinase with a view to beginning clinical trials in the future.

Andrew McLaughlin | alfa
Further information:
http://www.bath.ac.uk/news/2007/6/26/amphinase.html

Further reports about: Amphinase ribonuclease trials tumour

More articles from Life Sciences:

nachricht Warming ponds could accelerate climate change
21.02.2017 | University of Exeter

nachricht An alternative to opioids? Compound from marine snail is potent pain reliever
21.02.2017 | University of Utah

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Impacts of mass coral die-off on Indian Ocean reefs revealed

21.02.2017 | Earth Sciences

Novel breast tomosynthesis technique reduces screening recall rate

21.02.2017 | Medical Engineering

Use your Voice – and Smart Homes will “LISTEN”

21.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>